Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $81000.0.

  • Contineum Therapeutics' Depreciation & Amortization (CF) rose 3064.52% to $81000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $355000.0, marking a year-over-year increase of 5777.78%. This contributed to the annual value of $300000.0 for FY2024, which is 5000.0% up from last year.
  • Per Contineum Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $81000.0 for Q3 2025, which was up 3064.52% from $79000.0 recorded in Q2 2025.
  • Contineum Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $117000.0 during Q4 2024, with a 5-year trough of $42000.0 in Q2 2023.
  • For the 3-year period, Contineum Therapeutics' Depreciation & Amortization (CF) averaged around $67090.9, with its median value being $62000.0 (2024).
  • Within the past 5 years, the most significant YoY rise in Contineum Therapeutics' Depreciation & Amortization (CF) was 17857.14% (2024), while the steepest drop was 1643.84% (2024).
  • Over the past 3 years, Contineum Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $42000.0 in 2023, then surged by 178.57% to $117000.0 in 2024, then plummeted by 30.77% to $81000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $81000.0 for Q3 2025, versus $79000.0 for Q2 2025 and $78000.0 for Q1 2025.